Zentalis Pharmaceuticals (ZNTL) Profit After Tax (2019 - 2026)

Zentalis Pharmaceuticals' Profit After Tax history runs 8 years deep, the most recent figure standing at -$35.4 million for Q1 2026.

• On a quarterly basis, Profit After Tax rose 26.78% year-over-year to -$35.4 million in Q1 2026; TTM through Mar 2026 was -$124.1 million, a 44.64% increase from a year earlier, with the FY2025 full-year figure at -$137.1 million, up 17.37% from the prior year.
• Profit After Tax held at -$35.4 million in Q1 2026 per ZNTL's latest filing, from -$35.2 million in the prior quarter.
• Across five years, Profit After Tax topped out at $10.0 million in Q1 2024 and bottomed at -$112.6 million in Q2 2023.
• The 5-year median for Profit After Tax is -$54.4 million (2022), against an average of -$51.0 million.
• Across the five-year window, Profit After Tax plunged 1198.04% in 2022 and soared 115.88% in 2024, its largest moves.
• Year by year, Profit After Tax stood at -$55.0 million in 2022, then retreated by 10.86% to -$60.9 million in 2023, then increased by 22.05% to -$47.5 million in 2024, then advanced by 25.86% to -$35.2 million in 2025, then declined by 0.39% to -$35.4 million in 2026.
• Per Business Quant, the three latest ZNTL Profit After Tax figures stand at -$35.4 million (Q1 2026), -$35.2 million (Q4 2025), and -$26.7 million (Q3 2025).